drugset / Trial / NCT02385669
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.
Timeline
- Start
- 2015-04
- Primary completion
- 2019-09-18
- Completion
- 2019-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 6MHP | Vaccine | 200 ug | Subcutaneous |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |